Overview

Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)

Status:
Completed

Trial end date:
2009-10-01

Target enrollment:

Participant gender:

Summary

This study was designed to determine whether adjuvant vinorelbine plus cisplatin and endostar prolongs overall survival compare to vinorelbine plus cisplatin alone among patients with completely resected IB-IIIA non-small-cell lung cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Shanghai Jiao Tong University School of Medicine

Collaborators:

Shanghai Chest Hospital
Shanghai Municipal Science and Technology Commission
Simcere Pharmaceutical Co., Ltd

Treatments:

Cisplatin
Endostatins
Vinblastine
Vinorelbine